Peter Scott Chin - 04 Sep 2026 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Reporting relationship: Chief Medical Officer
Issuer ticker: DNLI
Reported as of: 04 Sep 2026
Net transaction value: -$36,868
SEC form: 4
Accepted by SEC: 09 Sep 2026, 16:44:33 UTC
Prior SEC filing: 21 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Nielsen, by power of attorney

Key filing fact

Peter Scott Chin filed Form 4 for Denali Therapeutics Inc. (DNLI) on 09 Sep 2026.

Key facts

This page summarizes Peter Scott Chin's Form 4 filing for Denali Therapeutics Inc. (DNLI).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 09 Sep 2026, 16:44.

Change

Previous filing in this sequence was filed on 21 Apr 2026.
Current net transaction value: -$36,868.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002124755 Primary reporting owner

Chin Peter Scott

Relationship: Chief Medical Officer
Address: C/O DENALI THERAPEUTICS INC., 161 OYSTER POINT BOULEVARD, SECOND FLOOR, SOUTH SAN FRANCISCO
Signature: /s/ Tyler Nielsen, by power of attorney
Signature date: 09 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DNLI transaction

Common Stock

Sale

Transaction value: $36,868
Shares: -1,654
Change %: -0.8%
Price: $22.29
Shares after: 204,538
Date: 04 Sep 2026
Ownership: Direct
Footnotes: F1, F2, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.

Footnote F2

The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $22.28 to $22.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Footnote F3

Includes 142,845 Unvested RSU's

Footnote F4

Includes 1,790 shares acquired under the ESPP Purchase on June 1, 2026.